Sandoz Group (OTCMKTS:SDZNY) & Jupiter Neurosciences (NASDAQ:JUNS) Head to Head Contrast

Sandoz Group (OTCMKTS:SDZNY) and Jupiter Neurosciences (NASDAQ:JUNS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Profitability

This table compares Sandoz Group and Jupiter Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Risk and Volatility

Sandoz Group has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Jupiter Neurosciences has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Sandoz Group and Jupiter Neurosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	1	0	3	3.50
Jupiter Neurosciences	1	0	0	0	1.00

Institutional and Insider Ownership

0.1% of Sandoz Group shares are held by institutional investors. 50.8% of Jupiter Neurosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Sandoz Group and Jupiter Neurosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$11.09 billion	3.20	$914.00 million	N/A	N/A
Jupiter Neurosciences	$40,448.00	217.16	-$8.65 million	($0.27)	-0.90

Sandoz Group has higher revenue and earnings than Jupiter Neurosciences.

Summary

Sandoz Group beats Jupiter Neurosciences on 7 of the 10 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.